# VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy

> **NCT05920343** · PHASE2,PHASE3 · RECRUITING · sponsor: **Ottawa Hospital Research Institute** · enrollment: 120 (estimated)

## Conditions studied

- Venous Thromboembolism
- Urologic Cancer

## Interventions

- **DRUG:** Rivaroxaban 10 MG
- **OTHER:** Placebo control

## Key facts

- **NCT ID:** NCT05920343
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05920343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05920343, "VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05920343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*